Porton Advanced Partners with Eureka Therapeutics to Accelerate T-Cell Therapy Development

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleas...

March 21, 2025 | Friday | News
Innovent & HUTCHMED Report Positive FRUSICA-2 Trial Results for Advanced RCC

 Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treat...

March 19, 2025 | Wednesday | News
TaiMed Biologics' TMB-365/TMB-380 Shows Strong Phase 2a Results for HIV Maintenance Therapy

TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 long-acting dual bNAb regime...

March 19, 2025 | Wednesday | News
Life Molecular Imaging & St. Teresa’s Hospital Launch Neuraceq® in Hong Kong for Early Alzheimer’s Diagnosis

Life Molecular Imaging (LMI) and St. Teresa's Hospital are pleased to announce that Florbetaben (18F) Injection (brand name: Neuraceq®) will be av...

March 18, 2025 | Tuesday | News
Dyne’s DYNE-251 Shows Sustained Functional Gains in DELIVER Trial for DMD

Dyne Therapeutics, Inc., a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscul...

March 18, 2025 | Tuesday | News
Bristol Myers Squibb Secures European Approval for Breyanzi® in Relapsed or Refractory Follicular Lymphoma

 Bristol Myers Squibb  announced that the European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; lis...

March 18, 2025 | Tuesday | News
Zynext Ventures Invests in Illexcor Therapeutics to Advance Next-Generation Oral Treatment for Sickle Cell Disease

 Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), announced its investment in Illexcor Ther...

March 13, 2025 | Thursday | News
GC Cell Launches Phase 1 Clinical Trial for GCC2005, a Novel CD5 CAR-NK Therapy Targeting T-Cell Lymphomas

GC Cell, under the leadership of CEO Sungyong Won, announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5...

March 13, 2025 | Thursday | News
Akeso’s Ivonescimab Phase III Study Results Published in The Lancet, Paving the Way for New NSCLC Treatment

Akeso, Inc. is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VE...

March 07, 2025 | Friday | News
BeiGene Wins FDA Approval for TEVIMBRA® in First-Line Esophageal Cancer Treatment

BeiGene, Ltd.  a global oncology company that intends to change its name to BeOne Medicines Ltd., announced the U.S. Food and Drug Administr...

March 06, 2025 | Thursday | News
Advancements in Tenosynovial Giant Cell Tumor Treatment with Surgery and Targeted Therapies

Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is primarily treate...

March 05, 2025 | Wednesday | News
CStone Begins Phase I Trial of CS2009 Trispecific Antibody for Solid Tumors

CStone Pharmaceuticals, an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced that&nbs...

March 04, 2025 | Tuesday | News
CARsgen Therapeutics Initiates First Patient Dosing of KJ-C2219 in Systemic Lupus Erythematosus Trial

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors,...

February 28, 2025 | Friday | News
Alumis to Present Data on A-005, a Novel TYK2 Inhibitor, at ACTRIMS Forum 2025

Alumis Inc. (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision app...

February 28, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close